ScoreWhy is Aurobindo Pharma Ltd. ?
1
The company is Net-Debt Free
2
Poor long term growth as Operating profit has grown by an annual rate 4.44% of over the last 5 years
3
Flat results in Jun 26
- ROCE(HY) Lowest at 12.10%
- DEBTORS TURNOVER RATIO(HY) Lowest at 4.71 times
4
With ROE of 9.4, it has a Fair valuation with a 2.5 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 55.33%, its profits have risen by 11.6% ; the PEG ratio of the company is 2
5
High Institutional Holdings at 41.48%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
6
Market Beating performance in long term as well as near term
- Along with generating 55.33% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Aurobindo Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Aurobindo Pharma for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Aurobindo Pharma
55.33%
2.13
25.98%
Sensex
-2.63%
-0.19
13.57%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
7.31%
EBIT Growth (5y)
4.44%
EBIT to Interest (avg)
22.33
Debt to EBITDA (avg)
1.18
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.79
Tax Ratio
31.54%
Dividend Payout Ratio
0
Pledged Shares
13.75%
Institutional Holding
41.48%
ROCE (avg)
13.54%
ROE (avg)
9.95%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
25
Industry P/E
37
Price to Book Value
2.55
EV to EBIT
17.97
EV to EBITDA
13.26
EV to Capital Employed
2.66
EV to Sales
2.69
PEG Ratio
2.03
Dividend Yield
0.24%
ROCE (Latest)
14.23%
ROE (Latest)
9.37%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
NET SALES(Q)
Highest at Rs 9,150.35 cr
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 9,870.29 cr
DEBT-EQUITY RATIO(HY)
Lowest at 0.21 times
PBDIT(Q)
Highest at Rs 1,881.06 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 20.56%
PBT LESS OI(Q)
Highest at Rs 1,291.04 cr.
PAT(Q)
Highest at Rs 1,059.93 cr.
EPS(Q)
Highest at Rs 17.95
-4What is not working for the Company
ROCE(HY)
Lowest at 12.10%
DEBTORS TURNOVER RATIO(HY)
Lowest at 4.71 times
Loading Valuation Snapshot...
Here's what is working for Aurobindo Pharma
Net Sales - Quarterly
Highest at Rs 9,150.35 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 1,881.06 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 20.56%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 1,291.04 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 1,059.93 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 17.95
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 9,870.29 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio - Half Yearly
Lowest at 0.21 times
in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Aurobindo Pharma
Debtors Turnover Ratio- Half Yearly
Lowest at 4.71 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
Non Operating Income - Quarterly
Highest at Rs 264.23 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
